Evaluation of Oncoxin-Viusid® in Head and Neck Cancer

Head Cancer Neck Clinical Trial

Official title:
"Combined Oncoxin-Viusid® Treatment With Radiotherapy and Chemotherapy in Patients With Head and Neck Cancer. Phase II, Randomized and Double-blind Study"

Status Completed

Clinical Trial Summary

Nutritional supplements containing antioxidants seem to decrease toxicity associated with Radiotherapy (RT) and Chemotherapy (CT) in patients with malignant head and neck tumors. Oncoxin-Viusid® (OV) is a nutritional supplement with antioxidant, immunomodulator and antitumor effects.

Clinical Trial Description

Objective

To assess the efficacy and safety of OV in patients with head and neck tumors during treatment with radio-chemotherapy.

Materials and Methods

Patients diagnosed with Head and Neck Carcinoma, and indicated to follow a radiotherapy treatment concurrent with Radiosensitizing Chemotherapy, were included in a phase II, randomized, prospective, controlled and double-blind study in two treatment arms: RT + CT + Placebo (n = 30) and RT + CT + OV (n = 30) during one year in a tertiary center (INOR), with the aim of evaluating the reduction of toxicities of RT-CT and improve the quality of life of patients during these oncospecific treatments. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03541772
Study type	Interventional
Source	Catalysis SL
Contact
Status	Completed
Phase	Phase 2
Start date	January 20, 2015
Completion date	October 30, 2017

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04251481` - Diffusion MRI for Head and Neck Cancer	N/A
Withdrawn	`NCT05472506` - Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer	Phase 1
Completed	`NCT04419077` - Interest of Virtual Reality to Prevent Cancer Patient Anxiety Before Chemotherapy or an Invasive Act	N/A
Not yet recruiting	`NCT05885490` - IReC-Bio and IReC Registry
Recruiting	`NCT04722523` - A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer	Phase 1
Completed	`NCT04237090` - Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel	Phase 3
Not yet recruiting	`NCT06366945` - Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC	Phase 2